ANGO Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -6.12% compared to AngioDynamics's net margin of 14.45%. AngioDynamics's return on equity of -20.83% beat Boston Scientific's return on equity of 9.57%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 61.35%. On the other hand Boston Scientific has an analysts' consensus of $116.96 which suggests that it could grow by 10.17%. Given that AngioDynamics has higher upside potential than Boston Scientific, analysts believe AngioDynamics is more attractive than Boston Scientific.

AngioDynamics has a beta of 0.582, which suggesting that the stock is 41.778% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are smaller than Boston Scientific quarterly revenues of $4.7B. AngioDynamics's net income of -$4.4M is lower than Boston Scientific's net income of $674M. Notably, AngioDynamics's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 77.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.40x versus 9.00x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of -6.12% compared to AngioDynamics's net margin of -5.14%. AngioDynamics's return on equity of -20.83% beat Integer Holdings's return on equity of 4.85%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 61.35%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 22.3%. Given that AngioDynamics has higher upside potential than Integer Holdings, analysts believe AngioDynamics is more attractive than Integer Holdings.

AngioDynamics has a beta of 0.582, which suggesting that the stock is 41.778% less volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are smaller than Integer Holdings quarterly revenues of $437.4M. AngioDynamics's net income of -$4.4M is higher than Integer Holdings's net income of -$22.5M. Notably, AngioDynamics's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 57.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.40x versus 2.45x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -6.12% compared to AngioDynamics's net margin of -45.89%. AngioDynamics's return on equity of -20.83% beat Masimo's return on equity of -39.91%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 61.35%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 15.79%. Given that AngioDynamics has higher upside potential than Masimo, analysts believe AngioDynamics is more attractive than Masimo.

AngioDynamics has a beta of 0.582, which suggesting that the stock is 41.778% less volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are smaller than Masimo quarterly revenues of $372M. AngioDynamics's net income of -$4.4M is higher than Masimo's net income of -$170.7M. Notably, AngioDynamics's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.40x versus 4.32x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of -6.12% compared to AngioDynamics's net margin of 8.48%. AngioDynamics's return on equity of -20.83% beat Merit Medical Systems's return on equity of 9.19%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 61.35%. On the other hand Merit Medical Systems has an analysts' consensus of $108.55 which suggests that it could grow by 12.48%. Given that AngioDynamics has higher upside potential than Merit Medical Systems, analysts believe AngioDynamics is more attractive than Merit Medical Systems.

AngioDynamics has a beta of 0.582, which suggesting that the stock is 41.778% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.439%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are smaller than Merit Medical Systems quarterly revenues of $355.4M. AngioDynamics's net income of -$4.4M is lower than Merit Medical Systems's net income of $30.1M. Notably, AngioDynamics's price-to-earnings ratio is -- while Merit Medical Systems's PE ratio is 47.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.40x versus 4.17x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.